Business & Practice

Kirkland Advises Bristol-Myers Squibb on $74 B Celgene Buy (1)

Jan. 3, 2019, 4:53 PMUpdated: Jan. 3, 2019, 8:35 PM

Large teams from Kirkland & Ellis and Wachtell Lipton Rosen & Katz played leading roles in Bristol-Myers Squibb’s $74 billion acquisition of Celgene Corp. announced Thursday.

The deal is uniting the two drugmakers, which are both engaged in a competitive market for new cancer treatments.

Kirkland represented BMS in the massive deal, which could amount to the largest merger in the pharma industry ever if approved by shareholders and regulators.

Kirkland’s team on the deal was led by corporate practice partners Daniel Wolf, Jonathan Davis, Ryan Brissette, and David Fox, according to a statement from the firm. That group was aided by nine additional partners from the firm’s capital markets, debt finance, IP, tax, antitrust, and executive compensation practice groups.

Celgene was represented by Wachtell corporate partners Steven Cohen, David Lam, and Edward Lee, with help from five other partners, one of counsel, and seven associates, according to a firm spokesperson. Those attorneys came from Wachtell’s corporate, executive compensation, antitrust, tax, and restructuring and finance groups.

If the deal goes through, Celgene shareholders will receive a single BMS share and $50 in cash for each share of Celgene, according to a separate press release on the deal.

(Added names of Wachtell attorneys in paragraph 5)

To contact the reporter on this story: Sam Skolnik in Washington at sskolnik@bloomberglaw.com

To contact the editor responsible for this story: Rebekah Mintzer at rmintzer@bloomberglaw.com

To read more articles log in.